## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of	of entity	
Visio	neering Technologies, Inc.	
ARBN		
616 1	56 248	
We (t	he entity) give ASX the following in	nformation.
	t 1 - All issues ust complete the relevant sections (attach si	heets if there is not enough space).
1	*Class of *securities issued or to be issued	CHESS Depositary Interests (CDIs)
	Г	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	66,666,667 CDIs
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for	As per existing CDIs. Each CDI represents the same number of shares of Class A Common Stock ( <b>Shares</b> ).

payment; if

securities, the conversion price and dates for conversion)

+convertible

Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

Yes. CDIs rank equally in all respects with other CDIs.

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

A\$0.045 per CDI

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Placement to sophisticated and professional investors – see announcement dated 30 December 2019 for further details.

Funds raised under the placement will be used to continue development of sales and marketing in the U.S., commercial launch into new geographies outside of the U.S., building inventory to meet growing sales, new product development (toric and multifocal toric lenses); and general working capital requirements.

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

Yes.

If Yes, complete sections 6b – 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

18 April 2019

6c Number of \*securities issued without security holder approval under rule 7.1

26,753,152

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	39,913,515	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Not applicable	
6f	Number of *securities issued under an exception in rule 7.2	Not applicable	
_	76.1	Van The incommiss of	CO 045 in 92 40/ (which
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	is greater than 75%)	\$0.045 is 82.4% (which of the 15 day VWAP December 2019, as 1A.3(a). Source: ASX.
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable.	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1	Under rule 7.1 – 33,11	7,120
	and release to ASX Market Announcements	Under rule 7.1A - Nil	
7	<sup>+</sup> Issue dates	8 January 2020	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		NY 1	1.01
		Number	+Class
8	Number and +class of all	465,801,819	CDIs
	+securities quoted on ASX	(assuming all issued	
	(including the +securities in	Shares are held as CDIs)	
	section 2 if applicable)		

		Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	Options to subscribe for 19,553,028 Shares (equivalent to the same number of CDIs) exercisable at various prices and expiring on various dates.	Unquoted options
		3,000,000 Convertible Notes	Convertible Notes
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Not applicable	

#### Part 2 - Pro rata issue

11	Is security holder approval required?	Not applicable
12	Is the issue renounceable or non-renounceable?	Not applicable
13	Ratio in which the *securities will be offered	Not applicable
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Not applicable
15	<sup>+</sup> Record date to determine entitlements	Not applicable
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable
17	Policy for deciding entitlements in relation to fractions	Not applicable
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.	Not applicable
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	Not applicable

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters	Not applicable
21	Amount of any underwriting fee or commission	Not applicable
22	Names of any brokers to the issue	Not applicable
23	Fee or commission payable to the broker to the issue	Not applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable.
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable
28	Date rights trading will begin (if applicable)	Not applicable
29	Date rights trading will end (if applicable)	Not applicable
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable
33	<sup>+</sup> Issue date	Not applicable

### Part 3 - Quotation of securities

34	Type ( <i>tick d</i>	of <sup>+</sup> securities one)
(a)	X	<sup>+</sup> Securities described in Part 1
(b)		All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entitie	es that	t have ticked box 34(a)
Additi	onal s	ecurities forming a new class of securities
Tick to docum		e you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional <sup>+</sup> securities

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
		Г	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	Glass

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 8 January 2020

(Director/ Company secretary)

Print name:

Julian Rockett

== == == ==

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	248,619,294 Shares (equivalent to the same number of CDIs)	
<ul> <li>Add the following:         <ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul> </li> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	22,222,222 CDIs (equivalent to the same number of Shares) approved by shareholders under ASX Listing Rule 7.4 on 2 July 2019 -12 June 2019 plus  45,887,740 Shares CDIs (equivalent to the same number of Shares) under ASX Listing Rule 7.2 Exception 1 – 4 July 2019 plus  82,405,896 CDIs (equivalent to the same number of Shares) under ASX Listing Rule 7.2 Exception 2 - 5 July 2019	
Subtract the number of fully paid  +ordinary securities cancelled during that 12 month period	Nil	
"A"	399,135,152 Shares (equivalent to the same number of CDIs)	

<sup>+</sup> See chapter 19 for defined terms.

04/03/2013 Appendix 3B Page 9

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	59,870,272	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	26,753,152 CDIs (equivalent to the same number of Shares) per this Appendix 3B.	
Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	26,753,152	
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1	-	
"A" x 0.15	59,870,272	
Note: number must be same as shown in Step 2		
Subtract "C"	26,753,152	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	33,117,120	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
399,135,152 Shares (equivalent to the same number of CDIs, assuming)		
0.10		
Note: this value cannot be changed		
39,913,515		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
39,913,515 (equivalent to the same number of Shares) per this Appendix 3B.		
39,913,515		

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	39,913,515	
Note: number must be same as shown in Step 2		
Subtract "E"	39,913,515	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	Nil	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.